Wedbush raised its target price for Crescent Biopharma to $31, up from $27.

Nov 13, 2026, 5:44 PM ETOpinionRead the original at marketscreener.com

Good for CBIO

Wedbush raised its price target and kept its Outperform rating, pointing to a more favorable view of Crescent Biopharma. The story gives no details about the company updates behind the change.

CBIO · Crescent Biopharma

AI read · Good for CBIO

The AI's read

That change suggests the firm sees more potential value after Crescent's recent company updates. The story gives no details from those updates, so the positive signal comes from the firm's view, not new operating results.

Get alerts for CBIO

Follow Crescent Biopharma (CBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CBIO

Free on the App Store and Google Play, or on the web.